Venture NAV Tracker / Private company
4D Molecular Therapeutics, Inc.
Headquarters—
Founded—
Last known round—
Reported valuation—
1 row is omitted from dispersion statistics under the degenerate-mark guard; each affected row states why.
Cross-fund comparison
Current disclosed marks
Included in the same underlying-company comparison band.
| Fund | Security type / annotations | Principal | Fair value | FV / principal | Rate | Maturity | Mark age vs round | Non-accrual |
|---|---|---|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | senior secured loanLevel 3 note discloses multiple approaches / cost or transaction-price buckets at asset-class level without identifying this position’s method; no individual method inferred. — Senior SecuredNo valuation basis was disclosed for this position. This is an annotation only and does not exclude the mark from comparison statistics.Omitted from statistics — security type is not an eligible fund-equity mark for dispersion. | $15.2MJun 30, 2026 · source ↗ | $15MJun 30, 2026 · source ↗ | 99.0%Jun 30, 2026 · source ↗ | Prime + 2.00%, Floor rate 8.75%, Cap rate 9.50%, 6.50% Exit FeeJun 30, 2026 · source ↗ | —Jun 30, 2026 · source ↗ | —Jun 30, 2026 · source ↗ | NoJun 30, 2026 · source ↗ |
Historical marks
Reported fair value by fund
Each bar is a disclosed position-quarter.